AbCellera Biologics (ABCL) Short-term Investments (2021 - 2026)

AbCellera Biologics has reported Short-term Investments for 6 years, with the latest figure at $25.0 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments changed 0.0% year-over-year to $25.0 million; the trailing twelve-month figure through Mar 2026 stood at $25.0 million (changed 0.0% YoY), and the FY2025 full-year result was $25.0 million, changed 0.0% from the prior year.
• Short-term Investments for Q1 2026 stood at $25.0 million, roughly flat from $25.0 million in the prior quarter.
• The five-year high for Short-term Investments was $25.0 million in Q4 2022, with the low at $25.0 million in Q4 2022.
• Historically, Short-term Investments has averaged $25.0 million across 5 years, with a median of $25.0 million in 2022.
• The largest YoY upside for Short-term Investments was 0.0% in 2022 against a maximum downside of 0.0% in 2022.
• AbCellera Biologics' Short-term Investments stood at $25.0 million in 2022, then changed by 0.0% to $25.0 million in 2023, then changed by 0.0% to $25.0 million in 2024, then changed by 0.0% to $25.0 million in 2025, then changed by 0.0% to $25.0 million in 2026.
• The last three Short-term Investments figures came in at $25.0 million (Q1 2026), $25.0 million (Q4 2025), and $25.0 million (Q3 2025), per Business Quant data.